Navjeevan Lifescience Private Limited

Navjeevan Lifescience Private Limited - pharma in Mumbai, Maharashtra, India. FY 2026 financials & compliance.
CIN U51909MH2002PTC136597 Incorporated 24 July 2002 ROC Mumbai HQ Mumbai, Maharashtra, India
Active Private Limited Company pharma
Data last updated
Revenue · FY 2015
₹3 Cr
▼ 92% YoY
Net loss · FY 2015
₹1.17 Cr
Net margin -38.9%
EBITDA · FY 2015
₹22.54 Lakh
EBITDA margin 7.5%
Authorised capital
₹1 Cr
Registered with MCA
Paid-up capital
₹99.05 Lakh
Issued & subscribed
Open charges
₹9.3 Cr
Satisfied ₹2.32 Cr
Company age
24 yrs
Est. 2002
Directors on board
4
As per MCA filings

About Navjeevan Lifescience Private Limited

Data last updated:

Navjeevan Lifescience Private Limited is a private limited company based in Mumbai, Maharashtra, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 24 July 2002 and has been in existence for over 24 years.

The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN U51909MH2002PTC136597. The company has 1 GST registration on record, which is no longer active.

The company has an authorised share capital of ₹1 Cr and a paid-up capital of ₹99.05 Lakh. It was formerly known as Navjeevan Mercantile Company Private Limited. It is led by directors including Bakul Pandharinath Patil and Kannan Krishnamurthy.

Its last annual general meeting (AGM) was held on 21 September 2015, and its latest financial statements are for the year ended 31 March 2015. The registered office is at D – 14 E/3 New Highway Park Thakur Complex Kandivali East, Mumbai, Maharashtra, India – 400101.

As per the financials filed for FY 2015, the company reported a revenue of ₹3 Cr, a decline of 92% compared to the previous year. For the same year it recorded a net loss of ₹1.17 Cr (net margin -38.9%) and EBITDA of ₹22.54 Lakh (EBITDA margin 7.5%). Revenue has declined at a compounded annual rate (CAGR) of 33% over three years.

As per MCA filings, the company has open charges of ₹9.3 Cr and satisfied charges of ₹2.32 Cr on record. Court records list 2 cases involving the company, including 2 filed against it; 1 case is pending.

The current compliance status is marked as active non-compliant by the Registrar of Companies.

Company details

CIN U51909MH2002PTC136597
Registration Number 136597
Incorporation Date 24 July 2002
ROC Mumbai
Listing Status Unlisted
Company Status Active
Date of Last AGM 21 September 2015
Date of Balance Sheet 31 March 2015
Compliance Status Active Non-Compliant

Contact details

Navjeevan Lifescience Private Limited's registered office is in Mumbai, Maharashtra. Its e-mail address is in the company report.

  • Email
  • Registered Address
    D – 14 E/3 New Highway Park Thakur Complex Kandivali East, Mumbai, Maharashtra, India – 400101
  • Industry
    Pharma, Drug Formulation & Development

To see the full contact details of Navjeevan Lifescience Private Limited, buy the company report.

Comprehensive company report
Navjeevan Lifescience Private Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Financials of Navjeevan Lifescience Private Limited

FY 2015 filings available

Navjeevan Lifescience Private Limited reported revenue of ₹3 Cr (down 92% YoY) for FY 2015.

Revenue · FY 2015
₹3 Cr ▼ 92%
Net loss · FY 2015
₹1.17 Cr margin -38.9%
EBITDA · FY 2015
₹22.54 Lakh margin 7.5%

Compounded Annual Growth Rate (CAGR)

Revenue CAGR growth
1 year
▼ 92%
3 years · compounded
▼ 33%
EBITDA CAGR growth
1 year
▼ 82%
3 years · compounded
▼ 71%

Revenue has declined at a compounded annual rate (CAGR) of 33% over three years, including a 92% fall in the latest year. EBITDA fell 82% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.

Financial Statement Summary

MetricsFY 2014-15
Profit and Loss Statement
Revenue from Operations
Other Income
Total Revenue₹3 Cr
Cost of Materials Consumed
Employee Benefit Expense
Finance Costs
Depreciation and Amortisation
Other Expenses
Total Expenses
EBITDA₹22.54 Lakh
Profit Before Tax
Tax Expense
Net Profit (PAT)-₹1.17 Cr
Balance Sheet
Share Capital
Reserves and Surplus
Net Worth (Total Equity)
Long-term Borrowings
Short-term Borrowings
Trade Payables
Total Liabilities
Fixed Assets
Investments
Inventories
Trade Receivables
Cash and Bank Balance
Total Assets

Financial Ratios

MetricsFY 2014-15
Profitability
EBITDA Margin7.5%
Net Profit Margin-38.9%
Return on Equity (ROE)
Return on Capital Employed (ROCE)
Return on Assets (ROA)
Liquidity and Debt
Current Ratio
Quick Ratio
Debt-to-Equity Ratio
Interest Coverage Ratio
Efficiency and Growth
Asset Turnover
Receivable Days
Payable Days
Inventory Days
Revenue Growth
Net Profit Growth

To see the full financial statements and ratios of Navjeevan Lifescience Private Limited, buy the company report.

Board of directors of Navjeevan Lifescience Private Limited

Navjeevan Lifescience has 4 current directors and 4 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors

Auditor

Navjeevan Lifescience Private Limited is audited by PEREIRA & SUBRAMANIAN for the financial year 2015.

Auditor firmFinancial yearFirm registration number
PEREIRA & SUBRAMANIANFY 2015112364W

Shareholding

The shareholding of Navjeevan Lifescience Private Limited is on record for FY 2015, split between promoters, domestic institutions, public shareholders and others.

Shareholder categoryFY 2015
Promoters
Domestic institutional investors (DII)
Public
Others

To see the full shareholding pattern of Navjeevan Lifescience Private Limited, buy the company report.

Charges & borrowings

Open charges
₹9.3 Cr
Satisfied charges
₹2.32 Cr
Breakdown by lending institutions
Others₹9.30 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
12 Dec 201310475725Others₹80 LakhOpen
01 Mar 201310420685Others₹8.5 CrOpen
05 Mar 200910193957Idbi Bank Limited₹1.5 CrSatisfied
18 Dec 200810135551Indian Bank₹7 LakhSatisfied
28 Feb 200690365745Punjab and Sind Bank₹75 LakhSatisfied

To see the full charge records of Navjeevan Lifescience Private Limited, buy the company report.

Total charge records: 5 View all charges

MSME payment delays

No delayed payments to MSME suppliers are on our record for Navjeevan Lifescience Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.

GST

Navjeevan Lifescience has 1 GST registration on record, and it has been cancelled or is inactive. Only active GST numbers are listed on this page.

Total GSTINs
1
Cancelled / inactive
1

To see the full GST registrations and return filing status of Navjeevan Lifescience Private Limited, buy the company report.

Recent activity

Navjeevan Lifescience Private Limited has 8 board changes on record since 2004: 4 appointments and 4 cessations. The latest: Harshad Champaklal Shah ceased to be Additional Director on 03 Feb 2022.

Charges
A charge with Others of Rs. 0.80 Cr registered on 12 Dec 2013 with Charge ID 10475725 was modified on 24 Dec 2024.
Charges
A charge with Others of Rs. 8.50 Cr registered on 01 Mar 2013 with Charge ID 10420685 was modified on 24 Dec 2024.
Ceased
Harshad Champaklal Shah ceased to be Additional Director.
Ceased
Rajendra Chandrakant Potnis ceased to be Additional Director.
AGM
Navjeevan Lifescience Private Limited last Annual general meeting of members was held on 21 Sep 2015 as per latest MCA records.
Filing
Navjeevan Lifescience Private Limited has filed its annual Financial statements for the year ended 31 Mar 2015 with Roc Mumbai I.
Charges
A charge with Others amounted to Rs. 0.80 Cr with Charge ID 10475725 was registered on 12 Dec 2013.
Charges
A charge registered on 05 Mar 2009 via Charge ID 10193957 with Idbi Bank Limited was fully satisfied on 03 Apr 2013.
Charges
A charge with Others amounted to Rs. 8.50 Cr with Charge ID 10420685 was registered on 01 Mar 2013.
Ceased
Mahalakshmi Kannan Krishnamurthy ceased to be Director.
Appointed
Harshad Champaklal Shah was appointed as Additional Director.
Appointed
Rajendra Chandrakant Potnis was appointed as Additional Director.

9 earlier events are in the company report.

Frequently asked questions

Navjeevan Lifescience is an active private limited company based in Mumbai, Maharashtra, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 24 July 2002 (24+ years old) and is registered under CIN U51909MH2002PTC136597.

Navjeevan Lifescience has 4 current directors:

The latest financial statements of Navjeevan Lifescience on record with the MCA are for the year ended 31 March 2015. Its last annual general meeting was held on 21 September 2015. Year-wise statements from 2015 are in the company report.

No. Navjeevan Lifescience has 1 GST registration on record and it is cancelled or inactive.

The CIN (Corporate Identification Number) of Navjeevan Lifescience is U51909MH2002PTC136597. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Navjeevan Lifescience has 2 court cases on record: 2 filed against it. 1 is pending.

Navjeevan Lifescience was incorporated on 24 July 2002, making it 24+ years old. It is registered with the Registrar of Companies, Mumbai.

Harshad Champaklal Shah ceased to be Additional Director on 03 Feb 2022. Rajendra Chandrakant Potnis ceased to be Additional Director on 24 May 2019. Mahalakshmi Kannan Krishnamurthy ceased to be Director on 14 Sep 2012. Navjeevan Lifescience has 8 board changes on record in total.

The registered office of Navjeevan Lifescience is at D – 14 E3 New Highway Park Thakur Complex Kandivali East, Mumbai, Maharashtra, India – 400101.

Navjeevan Lifescience operates in the pharma industry, in the drug formulation and development segment.